TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03156725
Drug: Ferrous Sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00651768
Drug: budesonide/formoterol
Normalized name: BUDESONIDE/FORMOTEROL
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00651768
Drug: Symbicort pMDI + budesonide HFA pMDI
Normalized name: budesonide / formoterol Metered Dose Inhaler [Symbicort]
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Symbicort 2 X 160/4.5mcg \& budesonide HFA pMDI 4 X 160mcg
Study: NCT01553591
Drug: Eluxadoline
Normalized name: ELUXADOLINE
DrugBank: Eluxadoline (DB09272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral tablets twice daily
Study: NCT00688948
Drug: Alfuzosin
Normalized name: Alfuzosin
DrugBank: Alfuzosin (DB00346)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alfuzosin 10 mg once daily po for 12 weeks
Study: NCT03959345
Drug: Combination therapy group
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult patients with MSSA bacteraemia will be randomized to Combination therapy group: patients will receive intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
Study: NCT00959894
Drug: Etravirine (Intelence)
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
Study: NCT00959894
Drug: Truvada
Normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
Study: NCT01729676
Drug: Degarelix or GnRH agonist
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix or GnRH agonist for treatment of prostate cancer according to physicians current practice
Study: NCT01976585
Drug: Poly-ICLC
Normalized name: Poly-ICLC
DrugBank: Hiltonol (DB17293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension. Each milliliter of Poly-ICLC for injection contains 2 mg/mL poly-IC, 1.5 mg/mL poly-L-lysine, and 5 mg/mL sodium carboxymethylcellulose in 0.9% sodium chloride solution and adjusted to pH 7.6-7.8 with sodium hydroxide.
Study: NCT03649139
Drug: sublingual immunotherapy drops
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: artemisia annua (sweet sagewort) allergen extract drops
Study: NCT01305941
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: everolimus 5 mg PO daily as two 2.5-mg tablets
Study: NCT01305941
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vinorelbine 25 mg/m2 will be administered via IV infusion over 6-10 minutes weekly.
Study: NCT01305941
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 mg/kg IV administered over 30 minutes weekly
Study: NCT01215019
Drug: Mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20% Mannitol, 1-5 doses as needed to control ICP
Study: NCT01215019
Drug: NaCl
Normalized name: NaCl
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3% sodium chloride injection, 1-5 doses, as needed to control ICP
Study: NCT03471611
Drug: Autologous CD34+ Cells
Normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose will be 1x10\^5 cells/kg, injected at the rate of 10 ml/min
Study: NCT03471611
Drug: Granulocyte Colony-Stimulating Factor (G-CSF)
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5mg/kg twice daily
Study: NCT00179998
Drug: Recombinant Human DNase (Pulmozyme)
Normalized name: Recombinant deoxyribonuclease (DNAse)
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg in 3 ml diluent delivered by nebulization given daily for 6 months with 3 ml diluent placebo delivered by nebulization given daily for 6 months
Study: NCT02768571
Drug: Cerebrolysin
Normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin- cerebrolysin 30 ml with 100 ml dilution/day \* 21 days with rehabilitation
Study: NCT03872232
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT02693769
Drug: fluticasone propionate/formoterol fumarate breath actuated inhaler
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02693769
Drug: Indacaterol maleate / glycopyrronium bromide capsules
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02537938
Drug: NGP 555
Normalized name: avalglucosidase alfa-ngpt
DrugBank: Avalglucosidase alfa (DB16099)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01464229
Drug: Iloperidone
Normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloperidone 1-8 mg for 4 weeks
Study: NCT00775736
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
Study: NCT00775736
Drug: biphasic insulin aspart 50
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
Study: NCT00252317
Drug: Captopril and Trandolapril
Normalized name: trandolapril and verapamil
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
Study: NCT00775736
Drug: biphasic insulin aspart 70
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
Study: NCT00437671
Drug: Tetanus Immune Globulin (Human)
Normalized name: Tetanus Immune Globulin (Human)
DrugBank: Tetanus immune globulin, human (DB11604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Based on package insert recommendation and recommendations of WHO
Study: NCT00252317
Drug: Captopril Test Dose and Trandolapril
Normalized name: trandolapril and verapamil
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
Study: NCT00980356
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Patients receive once daily 50 mg Vildagliptin
Study: NCT00051493
Drug: ALIMTA
Normalized name: Alimta
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00051493
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00531882
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg once a day
Study: NCT01737138
Drug: medicine
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agent, statins, platelet aggregation inhibitor, anticoagulants and so on.
Study: NCT01446991
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 240 mg loading dose followed by monthly 80 mg maintenance dose for 2-3 months
Study: NCT01446991
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 240 mg loading dose of Degarelix followed by 80 mg maintenance doses every month for a total duration of 6 months.
Study: NCT02426463
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02426463
Drug: oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05421962
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ninety patients were included and randomized to either fentanyl-propofol (Group FP, n: 30), ketamine-propofol (Group KP, n: 30) or propofol-control group (Group C, n: 30). Group FP patients received fentanyl and propofol, Group KP received ketamine and propofol and Group C, propofol.
Study: NCT03196986
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then switched to mil60 at 7.5mg/kg
Study: NCT00024180
Drug: romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01308086
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 12 cycles
Study: NCT01308086
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 12 cycles
Study: NCT01308086
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 8 cycles
Study: NCT01308086
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 6 cycles
Study: NCT01308086
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 4 cycles
Study: NCT01308086
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 6 cycles
Study: NCT00301223
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03769064
Drug: Methylphenidate 60 mg
Normalized name: methylphenidate 60 mg/24 hours oral capsule, extended release
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).
Study: NCT03769064
Drug: Treatment Phase Sequence 4213
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
Study: NCT03769064
Drug: Treatment Phase Sequence 2134
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
Study: NCT03769064
Drug: Treatment Phase Sequence 1342
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
Study: NCT00900666
Drug: botulinum toxin A (BTX-A)
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 200 Units BTX-A reconstituted with 2 cc sterile normal saline in 100:1 ratio. Teflon-coated EMG guidance for confirmation of injection into the Rectus femoris muscle in addition to utilizing standardized injection landmarks, the solution will be injected in 0.5 cc aliquots into 4 different injectate sites within the muscle.
Study: NCT00748345
Drug: Caspofungin (drug)
DrugBank: Caspofungin (DB00520)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pharmacokinetics of caspofungin in burn patients after a single usual dose (70 mg i.v.), in order to determine the optimal dose in this population
Study: NCT03769064
Drug: Treatment Phase Sequence 3421
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
Study: NCT04272541
Drug: Psychopharmacology intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention program consisted of psychopharmacology. This will be executed during 3 months.
Study: NCT04307953
Drug: AZD0530 Difumarate
Normalized name: Emedastine Difumarate
DrugBank: Emedastine (DB01084)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AZD0530 for the duration of the trial
Study: NCT00541125
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00921570
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: calcium channel blocker (Amlodipine 10 mg) during 12 weeks
Study: NCT02476890
Drug: Gefapixant 100 mg
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Gefapixant 100 mg (2 x 50 mg tablets), administered orally as a single dose in treatment Period 1 or treatment Period 2
Study: NCT00921570
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AII receptor blocker inhibitor (Valsartan 160 mg) during 12 weeks
Study: NCT02945852
Drug: apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: apatinib 500mg/d until progressive Disease
Study: NCT00194623
Drug: Botulinum Toxin A (Botox)
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT00082810
Drug: fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given intramuscularly
Study: NCT00082810
Drug: tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00354406
Drug: abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard i.v. bolus of abciximab is administered at time of randomization in arm A, and at time of primary angioplasty in arm B.
Study: NCT00243854
Drug: Tarceva
Normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tarceva: 100mg/day x 2 weeks (Days 1-14) +
Study: NCT03444506
Drug: Molo 1 (also referred as GSP 301-2 NS)
Normalized name: NS-2
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03444506
Drug: Molo 2 (also referred as GSP 301-1 NS)
Normalized name: NS-2
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03444506
Drug: PATANASE nasal spray
Normalized name: olopatadine Metered Dose Nasal Spray [PATANASE]
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03687827
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive insulin degludec U100 subcutaneous (s.c.) injection once daily for 36 weeks. Doses will be adjusted according to the fasting self-measured plasma glucose (SMPG) values. Participants earlier treated with one or more allowed oral antidiabetic drug(s) (OAD(s)), should continue their pre-trial OAD(s) treatment throughout the trial.
Study: NCT03687827
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive insulin glargine U100 s.c. injection once daily for 36 weeks. Doses will be adjusted according to the fasting SMPG values. Participants earlier treated with one or more allowed OAD(s), should continue their pre-trial OAD(s) treatment throughout the trial.
Study: NCT00625937
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00625937
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00625937
Drug: tegafur-gimeracil-oteracil potassium
Normalized name: tegafur
DrugBank: Oteracil (DB03209)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT02485444
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 IU oxytocin in 500 ml normal saline will be infused 100 ml/h i.v. after fetus is delivered
Study: NCT00509639
Drug: 10% Metronidazole Ointment
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 10% ointment applied perianally three times daily for four weeks. Placebo ointment applied perianally three times daily for four weeks
Study: NCT02950558
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single injection of ropivacaine immediately prior to surgery.
Study: NCT00288691
Drug: Asoprisnil (BAY86-5294)
Normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg/day
Study: NCT00288691
Drug: Asoprisnil (BAY86-5294)
Normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/day
Study: NCT01633528
Drug: Asprin
Normalized name: Easprin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg
Study: NCT00288691
Drug: Asoprisnil (BAY86-5294)
Normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg/day
Study: NCT03385967
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Addition of Dexmedetomidine in block .25mcg/kg of dexmedetomidine
Study: NCT03385967
Drug: ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care 0.5%ropivacaine
Study: NCT01018836
Drug: riluzole
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The first dose of Riluzole will be day 0 of study enrollment. WBRT must begin within 48 hours of the initiation of Riluzole therapy. At the completion of radiation, Riluzole should be discontinued and steroids should be tapered over the course of 1-3 weeks, at the discretion of the treating physicians.
Study: NCT02387450
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg per day
Study: NCT00987727
Drug: carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop in each eye three to six times daily, as needed
Study: NCT00987727
Drug: sodium hyaluronate 0.18% (VISMED® Multi)
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop in each eye three to six times daily, as needed
Study: NCT01272232
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide 3.0 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
Study: NCT01272232
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
Study: NCT02218645
Drug: Brotizolam
Normalized name: brotizolam
DrugBank: Brotizolam (DB09017)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00631358
Drug: Maxidex
Normalized name: Maxidex
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Maxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily
Study: NCT02807207
Drug: A: pacritinib
DrugBank: Pacritinib (DB11697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment A
Study: NCT02807207
Drug: C: moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment C
Study: NCT00002810
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00040443
Drug: CX516
Normalized name: CX516
DrugBank: CX516 (DB06247)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01344902
Drug: hexaminolevulinate HCl
Normalized name: HEXAMINOLEVULINATE HCL
DrugBank: Hexaminolevulinate (DB06261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg hexaminolevulinate HCl capsule 6 hours before colonoscopy
Study: NCT04026841
Drug: PD-1 antibody Sintilimab
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in experimental group receive the treatment of PD-1 antibody Sintilimab
Study: NCT01594229
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle.
Study: NCT01594229
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle.
Study: NCT01979393
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02894892
Drug: (A)Bismuth
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no